ZyVersa Therapeutics Faces Delisting Concerns

Ticker: ZVSA · Form: 8-K · Filed: May 30, 2025 · CIK: 1859007

Zyversa Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyZyversa Therapeutics, Inc. (ZVSA)
Form Type8-K
Filed DateMay 30, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: delisting, listing-standards, regulatory-filing

TL;DR

ZyVersa Therapeutics might get delisted, big trouble ahead.

AI Summary

ZyVersa Therapeutics, Inc. filed an 8-K on May 30, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly Larkspur Health Acquisition Corp., was incorporated in Delaware and has its principal executive offices in Weston, Florida.

Why It Matters

This filing indicates potential issues with ZyVersa Therapeutics' continued listing on an exchange, which could lead to significant stock price volatility and impact investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards is a severe event that can lead to the stock being traded on over-the-counter markets, significantly reducing liquidity and value.

Key Players & Entities

  • ZyVersa Therapeutics, Inc. (company) — Registrant
  • Larkspur Health Acquisition Corp. (company) — Former company name
  • May 27, 2025 (date) — Earliest event reported
  • May 30, 2025 (date) — Date of report
  • Delaware (jurisdiction) — State of incorporation
  • Weston, Florida (location) — Principal executive offices

FAQ

What specific listing rule or standard has ZyVersa Therapeutics failed to satisfy?

The filing does not specify the exact rule or standard that ZyVersa Therapeutics has failed to satisfy, only that a notice has been issued.

What is the effective date of the potential delisting?

The filing reports the event as of May 27, 2025, with the report filed on May 30, 2025. The exact effective date of delisting is not provided.

Has ZyVersa Therapeutics taken any steps to regain compliance with listing standards?

This 8-K filing does not contain information regarding any steps taken by ZyVersa Therapeutics to regain compliance.

What is the former name of ZyVersa Therapeutics, Inc.?

The former name of ZyVersa Therapeutics, Inc. was Larkspur Health Acquisition Corp.

Where are ZyVersa Therapeutics, Inc.'s principal executive offices located?

ZyVersa Therapeutics, Inc.'s principal executive offices are located at 2200 N. Commerce Parkway, Suite 208, Weston, Florida 33326.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 30, 2025 regarding ZyVersa Therapeutics, Inc. (ZVSA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.